

### Company Overview

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugate™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations.

### Cellecstar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma

Oct 2 2018, 8:00 AM EDT

### Cellecstar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Sep 27 2018, 8:30 AM EDT

### Cellecstar's CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma

Sep 25 2018, 8:30 AM EDT

### Stock Overview

|            |                       |
|------------|-----------------------|
| Symbol     | CLRB                  |
| Exchange   | Nasdaq                |
| Market Cap | 10.22m                |
| Last Price | \$2.69                |
| 52-Week    | \$2.025 - \$18.200001 |

10/15/2018 04:00 PM EDT

### Investor Relations

LHA Investor Relations  
Miriam Weber Miller  
T: 212-838-3777  
[MMiller@lhai.com](mailto:MMiller@lhai.com)

### Management Team

#### James Caruso

President, CEO and Director

#### Dr. John Friend

Chief Medical Officer

#### Jarrold Longcor

Chief Business Officer

#### Brian M. Posner

Chief Financial Officer

---

### Cellecstar Biosciences, Inc.

8383 Greenway Blvd, Suite 600  
Middleton, WI 53562

---

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.